INR 273.3
(0.64%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.88 Billion INR | 8.16% |
2022 | 1.74 Billion INR | 24.39% |
2021 | 1.4 Billion INR | -8.09% |
2020 | 1.52 Billion INR | -8.54% |
2019 | 1.66 Billion INR | 6.96% |
2018 | 1.56 Billion INR | 14.36% |
2017 | 1.36 Billion INR | -0.1% |
2016 | 1.36 Billion INR | -8.68% |
2015 | 1.49 Billion INR | -31.28% |
2014 | 2.17 Billion INR | -4.15% |
2013 | 2.27 Billion INR | 3.34% |
2012 | 2.19 Billion INR | -0.97% |
2011 | 2.21 Billion INR | 10.02% |
2010 | 2.01 Billion INR | 4.65% |
2009 | 1.92 Billion INR | -4.83% |
2008 | 2.02 Billion INR | 7.64% |
2007 | 1.88 Billion INR | 15.97% |
2006 | 1.62 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.9 Billion INR | 0.0% |
2023 Q2 | 1.84 Billion INR | 0.0% |
2023 Q4 | 1.88 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2023 FY | 1.88 Billion INR | 8.16% |
2023 Q3 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 1.74 Billion INR | 0.0% |
2022 Q2 | 1.49 Billion INR | 0.0% |
2022 FY | 1.74 Billion INR | 24.39% |
2022 Q1 | - INR | -100.0% |
2021 FY | 1.4 Billion INR | -8.09% |
2021 Q4 | 1.4 Billion INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 Q2 | 1.37 Billion INR | 0.0% |
2020 Q4 | 1.52 Billion INR | 0.0% |
2020 FY | 1.52 Billion INR | -8.54% |
2020 Q2 | 1.58 Billion INR | 0.0% |
2019 Q4 | 1.66 Billion INR | 0.0% |
2019 FY | 1.66 Billion INR | 6.96% |
2019 Q2 | 1.59 Billion INR | 0.0% |
2018 Q4 | 1.56 Billion INR | 0.0% |
2018 FY | 1.56 Billion INR | 14.36% |
2017 FY | 1.36 Billion INR | -0.1% |
2017 Q4 | 1.36 Billion INR | 0.0% |
2017 Q2 | 1.48 Billion INR | 0.0% |
2016 FY | 1.36 Billion INR | -8.68% |
2016 Q4 | 1.89 Billion INR | 0.0% |
2016 Q2 | 1.94 Billion INR | 0.0% |
2015 FY | 1.49 Billion INR | -31.28% |
2015 Q2 | 2.09 Billion INR | 0.0% |
2015 Q4 | 1.49 Billion INR | 0.0% |
2014 Q4 | 2.17 Billion INR | 0.0% |
2014 FY | 2.17 Billion INR | -4.15% |
2013 FY | 2.27 Billion INR | 3.34% |
2012 FY | 2.19 Billion INR | -0.97% |
2012 Q4 | 2.19 Billion INR | 0.0% |
2012 Q2 | 3.57 Billion INR | 0.0% |
2011 FY | 2.21 Billion INR | 10.02% |
2010 FY | 2.01 Billion INR | 4.65% |
2009 FY | 1.92 Billion INR | -4.83% |
2008 FY | 2.02 Billion INR | 7.64% |
2007 FY | 1.88 Billion INR | 15.97% |
2006 FY | 1.62 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Ajanta Pharma Limited | 10.71 Billion INR | 82.377% |
Amrutanjan Health Care Limited | 783.82 Million INR | -140.808% |
Sigachi Industries Limited | 2.53 Billion INR | 25.432% |
Bal Pharma Limited | 2.51 Billion INR | 24.839% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 17.557% |
Medico Remedies Limited | 438.24 Million INR | -330.699% |
Lasa Supergenerics Limited | 541.92 Million INR | -248.297% |
Venus Remedies Limited | 1.39 Billion INR | -35.519% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 51.514% |
Alpa Laboratories Limited | 307.12 Million INR | -514.58% |
Nectar Lifesciences Limited | 11.21 Billion INR | 83.174% |
Shilpa Medicare Limited | 12.93 Billion INR | 85.405% |
Aarti Drugs Limited | 11.5 Billion INR | 83.593% |
Lupin Limited | 96.23 Billion INR | 98.039% |
Aurobindo Pharma Limited | 152.2 Billion INR | 98.76% |
Zydus Lifesciences Limited | 71.79 Billion INR | 97.371% |
Windlas Biotech Limited | 1.76 Billion INR | -7.081% |
Suven Life Sciences Limited | 148.62 Million INR | -1170.016% |
Eris Lifesciences Limited | 38.26 Billion INR | 95.068% |
Valiant Laboratories Limited | 1.05 Billion INR | -78.36% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 82.373% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 86.655% |
Ipca Laboratories Limited | 33.74 Billion INR | 94.406% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 10.496% |
Achyut Healthcare Limited | 2.01 Million INR | -93666.071% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.972% |
Bajaj HealthCare Limited | 4.86 Billion INR | 61.224% |
RPG Life Sciences Limited | 1.38 Billion INR | -36.756% |
Mankind Pharma Limited | 23.87 Billion INR | 92.094% |
Laurus Labs Limited | 42.71 Billion INR | 95.581% |
Piramal Pharma Limited | 74 Billion INR | 97.449% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -61.989% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.7% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 88.402% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.101% |
Unichem Laboratories Limited | 8.06 Billion INR | 76.609% |
Sequent Scientific Limited | 8.27 Billion INR | 77.188% |
Novartis India Limited | 1.8 Billion INR | -4.798% |
Wanbury Limited | 3.15 Billion INR | 40.184% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 7.212% |
Wockhardt Limited | 39.87 Billion INR | 95.266% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -536.04% |
Jubilant Pharmova Limited | 61.27 Billion INR | 96.92% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 63.568% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.235% |
Divi's Laboratories Limited | 18.99 Billion INR | 90.061% |
NATCO Pharma Limited | 10.53 Billion INR | 82.078% |
Gufic Biosciences Limited | 5.59 Billion INR | 66.293% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 70.176% |
Ind-Swift Limited | 13.45 Billion INR | 85.97% |
Procter & Gamble Health Limited | 2.56 Billion INR | 26.304% |
FDC Limited | 3.7 Billion INR | 49.113% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 36.531% |
Granules India Limited | 22.95 Billion INR | 91.777% |
Medicamen Biotech Limited | 940.36 Million INR | -100.721% |
Alkem Laboratories Limited | 48.6 Billion INR | 96.117% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 48.444% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -553.573% |
Brooks Laboratories Limited | 248.6 Million INR | -659.253% |
Megasoft Limited | 1.85 Billion INR | -1.855% |
ZIM Laboratories Limited | 2.08 Billion INR | 9.288% |
Strides Pharma Science Limited | 37.68 Billion INR | 94.991% |
Neuland Laboratories Limited | 5.49 Billion INR | 65.673% |
Morepen Laboratories Limited | 4.45 Billion INR | 57.677% |
Hikal Limited | 12.99 Billion INR | 85.475% |
Indoco Remedies Limited | 10.34 Billion INR | 81.75% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 77.123% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -193.145% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 4.493% |
Hester Biosciences Limited | 3.59 Billion INR | 47.492% |